key: cord-0993356-y6qfex39
authors: Mulinari-Santos, Gabriel; Paino-Sant’Ana, Amanda; Okamoto, Roberta; Coléte, Juliana Zorzi; Neto, João Lopes Toledo
title: The Risk of Osseointegration in the Coronavirus Disease 19 Pandemic
date: 2021-07-15
journal: J Craniofac Surg
DOI: 10.1097/scs.0000000000007991
sha: a6adaee73226d99dca5cd97064f433efdaaf51d7
doc_id: 993356
cord_uid: y6qfex39

Coronavirus disease 19 (COVID-19) is associated with respiratory complications but also with alterations on bone metabolism. Coronavirus disease 19, therefore, might be a risk factor for osseointegration. Recent studies suggest that severe acute respiratory syndrome coronavirus 2 is related with bone abnormalities mainly for act via renin-angiotensin system. This report aims to list the bone alterations caused by coronavirus disease 19 and the possible consequences on the peri-implant bone healing. The current data add to the accumulating knowledge that coronavirus disease 19 may negatively impact the osseointegration and it requires further research.

C oronavirus disease 2019 (COVID-19) is a major risk factor for respiratory death worldwide, mainly for causing pulmonary complications such as pneumonia and acute respiratory failure. In addition, patients with COVID-19 are already associated with low serum calcium level, 1 decreased bone mineral density 2 and osteonecrosis. 3 Given the search of a favorable bone for implant placement, it is crucial to understand the consequences of COVID-19 on bone metabolism. Even though there is a lack of studies identifying COVID-19 as a risk factor in implantology.

Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) virus strain affect enzyme angiotensin-converting enzyme 2 (ACE2) expressed in epithelial cells of the respiratory tissues. 3 Besides the lungs, osteoblasts and osteoclasts express ACE2 on bone tissue. 4 Severe acute respiratory syndrome coronavirus 2infection causes deficiency of ACE2 and low production of Ang-(1-7). 3 Angiotensin-converting enzyme 2 downregulates angiotensin II (Ang II) and synthetizes Ang-(1-7). 3 Angiotensin II is responsible for bone reabsorption 5 and Ang-(1-7) has essential function to maintaining bone structure. 4 Consequently, ACE2 targeted by severe acute respiratory syndrome coronavirus 2may decrease bone mass. Thus, the depletion of ACE2 on bone tissue could impair osseointegration.

Another point, severe hypocalcaemia was highly prevalent in severe acute respiratory syndrome patients. 1 Thus, it could implicate a down regulation of calcium delivered during the osseointegration. Furthermore, COVID-19 promotes an excessive inflammation by proinflammation cytokines as interleukin-1, interleukin-6, and tumor necrosis factor a. 6 In attempt to stop this extreme inflammation, one of most proposed treatment to COVID-19 is the corticotherapy. 6 Prolonged corticotherapy can suppress bone mineral mass and bone formation. 6 Additionally, diabetes, smoking, vitamin D deficiency are conditions associated with severe COVID-19 patients and risk factors for osseiointegration.

Our present report may encourage studies to analyze periimplant bone healing in patients who have had COVID-19. Although the infected patient could be asymptomatic, diagnostic tests can be necessary to avoid metabolic effects of COVID-19 on bone tissue. This information reinforces the concerns about biosafety. In conclusion, the current article adds to the accumulating knowledge that COVID-19 is possible risk factor in implantology.

Low levels of total and ionized calcium in blood of COVID-19 patients

Reduced bone mineral density in male severe acute respiratory syndrome (SARS) patients in Hong Kong

Musculoskeletal complications of severe acute respiratory syndrome

The ACE-2/Ang1-7/ Mas cascade enhances bone structure and metabolism following angiotensin-II type 1 receptor blockade

Angiotensin II suppresses osteoblastic differentiation and mineralized nodule formation via AT1 receptor in ROS17/2.8 cells

Bone metabolism in SARS-CoV-2 disease: possible osteoimmunology and gender implications